Radius Health Inc (NASDAQ:RDUS) Receives $34.50 Average PT from Brokerages
Shares of Radius Health Inc (NASDAQ:RDUS) have been given a consensus rating of “Hold” by the eight brokerages that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $34.50.
A number of equities analysts recently commented on RDUS shares. Goldman Sachs Group upgraded Radius Health from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $26.00 to $38.00 in a research note on Wednesday, May 29th. Cowen reiterated a “hold” rating on shares of Radius Health in a research note on Thursday, August 8th. HC Wainwright reissued a “hold” rating on shares of Radius Health in a report on Thursday, May 9th. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Monday, May 6th. Finally, Citigroup reissued a “neutral” rating and issued a $24.00 target price on shares of Radius Health in a report on Thursday, May 30th.
NASDAQ:RDUS traded up $0.78 during mid-day trading on Friday, reaching $23.74. The stock had a trading volume of 12,888 shares, compared to its average volume of 414,905. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.86 and a beta of 0.95. Radius Health has a 1-year low of $12.81 and a 1-year high of $25.40. The stock’s 50 day simple moving average is $22.57 and its two-hundred day simple moving average is $21.20. The company has a debt-to-equity ratio of 6.75, a current ratio of 4.38 and a quick ratio of 4.28.
In other Radius Health news, Director Anthony Rosenberg sold 1,584 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $24.60, for a total value of $38,966.40. Following the transaction, the director now owns 8,716 shares of the company’s stock, valued at $214,413.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Joseph Francis Kelly bought 2,500 shares of the business’s stock in a transaction on Friday, June 7th. The stock was acquired at an average cost of $21.81 per share, for a total transaction of $54,525.00. Following the acquisition, the vice president now directly owns 7,500 shares of the company’s stock, valued at $163,575. The disclosure for this purchase can be found here. Company insiders own 4.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new position in Radius Health in the fourth quarter worth about $4,057,000. Emerald Advisers LLC raised its holdings in shares of Radius Health by 596.4% during the second quarter. Emerald Advisers LLC now owns 662,113 shares of the biopharmaceutical company’s stock valued at $16,129,000 after buying an additional 567,038 shares during the last quarter. Pictet Asset Management Ltd. raised its holdings in shares of Radius Health by 50.0% during the first quarter. Pictet Asset Management Ltd. now owns 242,500 shares of the biopharmaceutical company’s stock valued at $4,835,000 after buying an additional 80,800 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Radius Health by 1,098.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 189,400 shares of the biopharmaceutical company’s stock valued at $3,739,000 after buying an additional 173,600 shares during the last quarter. Finally, AlphaCrest Capital Management LLC bought a new stake in shares of Radius Health during the first quarter valued at approximately $502,000.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Story: What are retained earnings?
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.